https://scholars.lib.ntu.edu.tw/handle/123456789/487247
標題: | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO | 作者: | Chen L.-T. Martinelli E. ANN-LII CHENG Pentheroudakis G. Qin S. Bhattacharyya G.S. Ikeda M. Lim H.-Y. Ho G.F. Choo S.P. Ren Z. Malhotra H. Ueno M. Ryoo B.-Y. Kiang T.C. Tai D. Vogel A. Cervantes A. Lu S.-N. Yen C.-J. Huang Y.-H. Chen S.-C. CHIUN HSU YING-CHUN SHEN Tabernero J. Yen Y. CHIH-HUNG HSU Yoshino T. Douillard J.-Y. |
公開日期: | 2020 | 出版社: | Elsevier Ltd | 卷: | 31 | 期: | 3 | 起(迄)頁: | 334-351 | 來源出版物: | Annals of Oncology | 摘要: | The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiwan Joint Cancer Conference (TJCC) in May 2019 in Taipei. The aim was to adapt the ESMO 2018 guidelines to take into account both the ethnic and the geographic differences in practice associated with the treatment of HCC in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with intermediate and advanced/relapsed HCC representing the oncology societies of Taiwan (TOS), China (CSCO), India (ISMPO) Japan (JSMO), Korea (KSMO), Malaysia (MOS) and Singapore (SSO). The voting was based on scientific evidence, and was independent of the current treatment practices, the drug availability and reimbursement situations in the individual participating Asian countries. ? 2020 European Society for Medical Oncology |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078748808&doi=10.1016%2fj.annonc.2019.12.001&partnerID=40&md5=9e767425aaccd7223aa95ea3841ce2f1 https://scholars.lib.ntu.edu.tw/handle/123456789/487247 |
ISSN: | 0923-7534 | DOI: | 10.1016/j.annonc.2019.12.001 | SDG/關鍵字: | atezolizumab; bevacizumab; cabozantinib; cisplatin; fluorouracil; folinic acid; lenvatinib; nivolumab; oxaliplatin; pembrolizumab; ramucirumab; regorafenib; sorafenib; Article; cancer diagnosis; cancer epidemiology; cancer incidence; cancer patient; cancer staging; cancer therapy; China; drug approval; follow up; human; India; Japan; Korea; liver cell carcinoma; Malaysia; medical society; practice guideline; priority journal; reimbursement; risk assessment; Singapore; Taiwan; treatment response; Asia; liver cell carcinoma; liver tumor; oncology; practice guideline; South Korea; Asia; Carcinoma, Hepatocellular; China; Humans; India; Japan; Liver Neoplasms; Malaysia; Medical Oncology; Republic of Korea; Taiwan |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。